Table 1.
Summary of cases who took extended courses of Paxlovid outside the context of an acute re-infection and experienced any improvement
| Case # | Age, gender | Date of COVID infection(s) | Likely variant | Initiation of Long COVID symptoms | COVID vaccinations | Date and length of extended course of Paxlovid | Short-term improvement with Paxlovid | Sustained improvement with Paxlovid | Adverse effects of Paxlovid |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 56 y.o. man | March 2020 | original wild type | Jul 2020 | 2021 (Feb, Mar, Nov), 2022 (May, Nov) | Jan 2023 (15 d) | y | y | |
| 2 | 45 y.o. woman | March 2022 | omicron | Apr 2022 | 2021 (Jan, Feb, 2021), 2022 (Oct) | Feb 2023 (15 d) | y | y | y |
| 3 | 25 y.o. woman | May 2022 | omicron | May 2022 | 2021 (Apr, Apr, Nov) | Jan 2023 (10 d) | y | y | |
| 4 | 51 y.o. man | Aug 2022 | omicron | Aug 2022 | 2021 (Apr, May, Nov), 2022 (Aug) | Mar 2023 (15 d) | y | y | |
| 5 | woman, age undisclosed | March 2020 | original wild type | Mar 2020 | 5 vaccines beginning in 2021 | Jun 2023 (10 d) | y | y | |
| 6 | 40 y.o. man | March 2020 | original wild type | May 2020 | Not specified | Sept 2022 (30 d) | y | y | |
| 7 | 30 y.o. man | May 2022, July 2022 | omicron, omicron | Jul 2022 | 2021 (Mar, April, Nov) | May 2023 (15 d) | y |
For individuals indicated as having short-term improvements but not sustained improvements, this means that any improvements observed eventually dissipated. For case 4, he started valacyclovir one day before he started the long course of nirmatrelvir/ritonavir, so it is difficult to determine if the benefits are due to nirmaltrelvir/ritonavir, valacyclovir, or both.